The Continuing Question of Adjuvant Therapy in Clear Cell Renal Cell Carcinoma

SIMPLE SUMMARY: Treatment options after radical nephrectomy for clear cell renal cell carcinoma (ccRCC) have been studied extensively in large randomized clinical trials. Currently, two therapies are approved for patients to receive for one year: pembrolizumab or sunitinib. Newer advances are being...

Descripción completa

Detalles Bibliográficos
Autores principales: Berg, Stephanie A., McGregor, Bradley A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776072/
https://www.ncbi.nlm.nih.gov/pubmed/36551504
http://dx.doi.org/10.3390/cancers14246018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776072/
https://www.ncbi.nlm.nih.gov/pubmed/36551504
http://dx.doi.org/10.3390/cancers14246018

Ejemplares similares